共 21 条
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
被引:38
作者:
Perkins, Daniel
[1
]
Sarris, Jerome
[2
,3
]
Rossell, Susan
[4
,5
]
Bonomo, Yvonne
[6
,7
]
Forbes, David
[8
]
Davey, Christopher
[8
]
Hoyer, Daniel
[9
,10
]
Loo, Colleen
[11
,12
]
Murray, Greg
[4
]
Hood, Sean
[13
]
Schubert, Violeta
[1
]
Galvao-Coelho, Nicole Leite
[14
]
O'Donnell, Meaghen
[8
]
Carter, Olivia
[15
]
Liknaitzky, Paul
[16
,17
]
Williams, Martin
[18
]
Siskind, Dan
[19
,20
]
Penington, David
[21
]
Berk, Michael
[8
,22
,23
,24
]
Castle, David
[25
,26
]
机构:
[1] Univ Melbourne, Sch Social & Polit Sci, John Medley Bldg, Parkville, Vic 3052, Australia
[2] Western Sydney Univ, NICM Hlth Res Inst, Westmead, NSW, Australia
[3] Univ Melbourne, Dept Psychiat, Professorial Unit, Melbourne Clin, Melbourne, Vic, Australia
[4] Swinburne Univ, Ctr Mental Hlth, Hawthorn, Vic, Australia
[5] St Vincents Hosp, Dept Psychiat, Fitzroy, Vic, Australia
[6] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[7] St Vincents Hosp, Dept Addict, Melbourne, Vic, Australia
[8] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia
[9] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia
[10] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA
[11] Univ New South Wales, Sch Psychiat, Sydney, NSW, Australia
[12] Black Dog Inst, Sydney, NSW, Australia
[13] Univ Western Australia, Fac Hlth & Med Sci, UWA Med Sch, Div Psychiat, Perth, WA, Australia
[14] Univ Fed Rio Grande do Norte, Dept Physiol & Behav, Natal, RN, Brazil
[15] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia
[16] Monash Univ, Sch Psychol Sci, Turner Inst, Clayton, Vic, Australia
[17] Monash Univ, Sch Clin Sci, Dept Psychiat, Clayton, Vic, Australia
[18] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem & Drug Act, Parkville, Vic, Australia
[19] Metro South Addict & Mental Hlth Serv, Mobile Intens Rehabil Team, Brisbane, Qld, Australia
[20] Univ Queensland, Sch Clin Med, Brisbane, Qld, Australia
[21] Univ Melbourne, Vice Chancellors Off, Melbourne, Vic, Australia
[22] Deakin Univ, IMPACT Res Inst, Sch Med, Geelong, Vic, Australia
[23] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia
[24] Orygen Natl Ctr Excellence Youth Mental Hlth, Parkville, Vic, Australia
[25] Univ Toronto, Ctr Addict & Mental Hlth, Ctr Complex Intervent, Toronto, ON, Canada
[26] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
基金:
澳大利亚国家健康与医学研究理事会;
英国医学研究理事会;
关键词:
Psychedelic-assisted psychotherapy;
psilocybin;
ayahuasca;
LSD;
MDMA;
psychiatry;
mental disorders;
neuroscience;
post-traumatic stress disorder;
depression;
D O I:
10.1177/0004867421998785
中图分类号:
R749 [精神病学];
学科分类号:
100205 ;
摘要:
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the 'Clinical Memorandum on Psychedelics' recently released by the Royal Australian and New Zealand College of Psychiatrists and note subsequent developments including the application for down-scheduling of psilocybin and 3,4-methylenedioxymethamphetamine presently being considered by the Therapeutic Goods Administration and approvals for access via the Special Access Scheme. We suggest that this field is worthy of rigorous research to assess potential benefits, address safety parameters and clarify therapeutic mechanisms. To this end, we outline recent research findings, provide an overview of current knowledge relating to mechanisms of action and discuss salient aspects of the psychedelic-assisted psychotherapy treatment model. The sum of this research points towards medicinal psychedelics as a potential new class of psychiatric treatments when used within a medically supervised framework with integrated psychotherapeutic support. However, before widespread translation into clinical use can occur, appropriately designed and sufficiently powered trials are required to detect both potential positive and negative outcomes. Unique safety and regulatory challenges also need to be addressed. As for any new medical therapy, psychedelic research needs to be conducted in a rigorous manner, through the dispassionate lens of scientific enquiry. Carte blanche availability to practitioners, without specific protocols and appropriate training, would be potentially harmful to individuals and detrimental to the field.
引用
收藏
页码:1127 / 1133
页数:7
相关论文